Navigation Links
Herceptin May Carry Higher Heart Risks for Women Than Thought
Date:11/15/2012

By Kathleen Doheny
HealthDay Reporter

THURSDAY, Nov. 15 (HealthDay News) -- The risks of developing heart problems while taking the breast cancer drug Herceptin alone or with other anti-cancer drugs may be even higher for older women than thought, new research indicates.

Herceptin (trastuzumab) has long been used to treat breast cancers that overproduce HER-2, also known as human epidermal growth factor. The drug improves disease-free and overall survival, but experts have known that it increases the risk of heart failure because it can affect the ability of the heart to pump blood. It can also raise the chances of developing cardiomyopathy, where the heart muscle becomes enlarged or rigid.

Now, a new study that focused on women aged 67 and older has found that the risk may be higher than believed. The report is published online Nov. 14 in the Journal of the American College of Cardiology.

For older women, the message is this, said study leader Dr. Jersey Chen, an assistant professor of cardiology at the Yale University School of Medicine: "You should know that your risk of developing heart failure or cardiomyopathy may be higher than what is quoted to you [by your doctor]."

Those earlier estimates, Chen said, are based on clinical trials that mainly looked at younger and, in some cases, healthier women.

In those studies, the risk of heart failure, for instance, increased by about 1.6 percent for women on Herceptin. In Chen's new research, the team found that Herceptin or Herceptin given with the anti-cancer drugs known as anthracyclines, raise the risk of either heart failure or cardiomyopathy by about 9 percent in the first year compared to no chemotherapy.

Chen looked at more than 45,000 women, aged 67 and older, who had early-stage breast cancer and were treated with a variety of regimens from 2000 to 2007.

The researchers followed them for three years to see who developed heart problems.

The rates of either heart failure or cardiomyopathy were higher for those getting Herceptin and anthracyclines, either separately or together, than those who did not receive chemotherapy.

Put in other terms, for every 100 patients, 32 of those on Herceptin and 42 of those on Herceptin and anthracycline had developed cardiac problems by the three-year mark, compared to 19 of every 100 patients who did not get adjuvant therapy.

Women who are on these therapies, Chen said, may need to seek additional monitoring. They should discuss the risks and benefits of the treatment with their doctors.

Women should also put these risks in perspective, said Dr. Xianglin Du, a professor of epidemiology at the University of Texas Health Science Center at Houston who has also studied cardiac problems linked with the drugs.

"Overall, their findings were consistent with what were found in our study published a year ago," she said. "Because many studies demonstrated that the addition of trastuzumab to chemotherapy significantly prolongs survival, women with breast cancer are advised to talk to their oncologists to weigh the benefits against potential risks for a better informed decision."

She agreed that closer monitoring may be needed.

The study was funded by the American Heart Association and a collaborative agreement by Memorial Sloan-Kettering Cancer Center. One co-author is a consultant to Celegene, GlaxoSmithKline, Abraxis Bioscience, GTX, Amgen and Genentech.

More information

To learn more about Herceptin, visit the U.S. National Library of Medicine.

SOURCES: Jersey Chen, M.D., M.P.H., assistant professor, cardiology, Yale University School of Medicine, New Haven, Conn.; Xianglin Du, M.D., Ph.D., professor, epidemiology, University of Texas Health Science Center, Houston; Nov. 14, 2012, Journal of the American College of Cardiology, online


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. African Chimps Carry Drug-Resistant, Human-Linked Staph
2. Some Schools Dont Let Kids Carry Asthma Inhalers
3. People Carrying Guns May Appear Bigger Than They Are
4. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
5. Higher proportion of California children uninsured than in US, USC analysis shows
6. Diabetic patients have higher prevalence of hearing impairment
7. Job stress and mental health problems contribute to higher rates of physician suicide
8. Pregnant Women With Bipolar Disorder May Have Higher Risk of Premature Birth
9. Common Antidepressants Tied to Higher Bleeding Risk in Warfarin Users: Study
10. Heart Failure Patients May Be at Higher Risk for Cancer: Study
11. Higher dietary glycemic load linked to worse colon cancer survival
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Herceptin May Carry Higher Heart Risks for Women Than Thought 
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a ... new strategies to reduce waste, and support renewable energy. They believe this is a ... nature to find solutions for health issues, and maintain that destroying the environment in ...
(Date:4/24/2017)... ... April 24, 2017 , ... The California Dental Association Foundation’s two-day volunteer dental ... 1,961 people during the April 22-23 event at the San Mateo Event Center. ... barriers to care, CDA Cares educates the public and policymakers about the importance of ...
(Date:4/24/2017)... McLean, Virginia (PRWEB) , ... April 24, 2017 ... ... have announced that they are seeking public support to bring their novel lifesaving ... in appearance, wearable device packed with medical-grade sensors, specially designed to read a ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, ... diagnosed globally; approximately 25,000 of them will be malignant.(1) As research into precision ... type of healthcare model in the diagnosis and treatment of brain tumors. Healthcare ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) ... Jim Walter Blvd, for an educational and exciting 2-day program. , An attendee ... hearing this before they approach patients” about the course entitled Ain't Misbehavin': Decreasing and ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical ... Gynecology markets with innovative and proprietary products, will release ... 2017 after the market close on Tuesday, May 2, ... conference call and webcast to discuss its financial results ... 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
(Date:4/18/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 6.35% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and ... today announced the signing of a three-year exclusive ... will deploy a dedicated sales team to introduce ... U.S., primarily focused in 13 states in the ...
Breaking Medicine Technology: